American Research & Management Company’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $2.45M | Hold |
49,174
| – | – | 0.68% | 45 |
|
|
2022
Q2 | $2.74M | Buy |
49,174
+174
| +0.4% | +$9.65K | 0.7% | 43 |
|
|
2022
Q1 | $2.72M | Sell |
49,000
-376
| -0.8% | -$19.3K | 0.6% | 51 |
|
|
2021
Q4 | $2.77M | Sell |
49,376
-200
| -0.4% | -$10.8K | 0.6% | 50 |
|
|
2021
Q3 | $2.38M | Sell |
49,576
-750
| -1% | -$36.3K | 0.55% | 52 |
|
|
2021
Q2 | $2.11M | Sell |
50,326
-60
| -0.1% | -$2.33K | 0.48% | 53 |
|
|
2021
Q1 | $1.7M | Sell |
50,386
-550
| -1% | -$19.6K | 0.41% | 57 |
|
|
2020
Q4 | $1.78M | Sell |
50,936
-450
| -0.9% | -$15.6K | 0.46% | 54 |
|
|
2020
Q3 | $1.78M | Sell |
51,386
-400
| -0.8% | -$13.3K | 0.52% | 51 |
|
|
2020
Q2 | $1.7M | Sell |
51,786
-264
| -0.5% | -$8.43K | 0.51% | 50 |
|
|
2020
Q1 | $1.57M | Sell |
52,050
-3,900
| -7% | -$116K | 0.6% | 49 |
|
|
2019
Q4 | $1.62M | Buy |
55,950
+1,600
| +3% | +$44.3K | 0.48% | 53 |
|
|
2019
Q3 | $1.41M | Sell |
54,350
-700
| -1% | -$17.7K | 0.42% | 60 |
|
|
2019
Q2 | $1.41M | Buy |
55,050
+900
| +2% | +$22.2K | 0.42% | 59 |
|
|
2019
Q1 | $1.42M | Hold |
54,150
| – | – | 0.4% | 59 |
|
|
2018
Q4 | $1.25M | Buy |
54,150
+2,500
| +5% | +$55.6K | 0.42% | 58 |
|
|
2018
Q3 | $1.22M | Sell |
51,650
-850
| -2% | -$20.7K | 0.36% | 60 |
|
|
2018
Q2 | $1.21M | Buy |
52,500
+8,050
| +18% | +$191K | 0.42% | 53 |
|
|
2018
Q1 | $1.09M | Hold |
44,450
| – | – | 0.36% | 58 |
|
|
2017
Q4 | $1.19M | Sell |
44,450
-50
| -0.1% | -$1.27K | 0.37% | 59 |
|
|
2017
Q3 | $1.07M | Buy |
44,500
+3,400
| +8% | +$76.8K | 0.35% | 63 |
|
|
2017
Q2 | $881K | Sell |
41,100
-1,200
| -3% | -$24.2K | 0.29% | 68 |
|
|
2017
Q1 | $725K | Sell |
42,300
-200
| -0.5% | -$3.48K | 0.26% | 65 |
|
|
2016
Q4 | $762K | Sell |
42,500
-3,000
| -7% | -$54.4K | 0.26% | 68 |
|
|
2016
Q3 | $946K | Sell |
45,500
-500
| -1% | -$12.4K | 0.34% | 59 |
|
|
2016
Q2 | $1.24M | Sell |
46,000
-3,100
| -6% | -$85K | 0.48% | 55 |
|
|
2016
Q1 | $1.33M | Buy |
49,100
+2,310
| +5% | +$61.9K | 0.56% | 50 |
|
|
2015
Q4 | $1.36M | Sell |
46,790
-400
| -0.8% | -$11.1K | 0.58% | 50 |
|
|
2015
Q3 | $1.28M | Hold |
47,190
| – | – | 0.56% | 53 |
|
|
2015
Q2 | $1.29M | Buy |
47,190
+190
| +0.4% | +$5.34K | 0.52% | 54 |
|
|
2015
Q1 | $1.25M | Sell |
47,000
-7,000
| -13% | -$161K | 0.51% | 53 |
|
|
2014
Q4 | $1.14M | Hold |
54,000
| – | – | 0.42% | 57 |
|
|
2014
Q3 | $1.29M | Sell |
54,000
-2,500
| -4% | -$57.5K | 0.46% | 57 |
|
|
2014
Q2 | $1.3M | Sell |
56,500
-2,200
| -4% | -$48.6K | 0.45% | 57 |
|
|
2014
Q1 | $1.34M | Sell |
58,700
-5,300
| -8% | -$113K | 0.48% | 58 |
|
|
2013
Q4 | $1.18M | Sell |
64,000
-2,000
| -3% | -$34.9K | 0.42% | 59 |
|
|
2013
Q3 | $1.12M | Sell |
66,000
-12,000
| -15% | -$202K | 0.44% | 58 |
|
|
2013
Q2 | $1.21M | Buy |
+78,000
| New | +$1.3M | 0.49% | 54 |
|
Other funds holding NVO
F
American Research & Management Company's NVO Position: Q3 2022 in Review
American Research & Management Company held its Novo Nordisk (NVO) position steady in Q3 2022 at 49,174 shares worth $2.45M. The position accounts for 0.68% of the portfolio, ranked #45.
American Research & Management Company first reported a position in NVO in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.77M in Q4 2021. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.
- American Research & Management Company held 49,174 shares of Novo Nordisk worth $2.45M as of Q3 2022.
- American Research & Management Company left its Novo Nordisk share count unchanged in Q3 2022.
- Novo Nordisk made up 0.68% of American Research & Management Company's portfolio in Q3 2022, its #45 holding.
- American Research & Management Company first reported a position in Novo Nordisk in Q2 2013 and has held it in 38 quarters since.
- American Research & Management Company's Novo Nordisk position peaked at $2.77M in Q4 2021.
- 907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.
Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.